Shelton Capital Management Neurocrine Biosciences Inc Transaction History

Shelton Capital Management

$3.99 Billion
Q4 2024

A detailed history of Shelton Capital Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Shelton Capital Management holds 3,811 shares of NBIX stock, worth $431,062. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,811

Previous 3,978 4.2%

Holding current value

$431,062

Previous $457,000 13.79%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$111.62 - $139.44 $18,640 - $23,286	-167 Reduced 4.2%	3,811 $520,000
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $8,708 - $11,639	-76 Reduced 1.87%	3,978 $457,000
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $12,562 - $13,746	-96 Reduced 2.31%	4,054 $558,000
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $16,300 - $17,967	-125 Reduced 2.92%	4,150 $572,000
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $25,562 - $31,995	-241 Reduced 5.34%	4,275 $563,000
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $23,034 - $28,689	-245 Reduced 5.15%	4,516 $508,000
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $12,176 - $14,262	-136 Reduced 2.78%	4,761 $448,000
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $12,699 - $15,120	-119 Reduced 2.37%	4,897 $584,000
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $15,292 - $20,394	-192 Reduced 3.69%	5,016 $427,000
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $465,751 - $532,622	5,208 New	5,208 $507,000

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.

Account

Shelton Capital Management Neurocrine Biosciences Inc Transaction History